Evidence map›Paper›PMID 34838022›Full record

ReviewCancer cell international2021

Clinicopathological and prognostic significance of speckle-type POZ protein in cancers: a systematic review and meta-analysis.

Yan He, Jun Chen, Xingchen Peng, Yanli Xia, Yonglin Su

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yan He *Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Jun Chen *Department of Ophalmology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Xingchen PengDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Yanli XiaCollege of Food and Biological Engineering, Chengdu University, Chengdu, 610041, Sichuan, People's Republic of China. xiayanli@cdu.edu.cn.
Yonglin SuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China. scuhxsyl@163.com.ORCID http://orcid.org/0000-0002-5035-2667
Sichuan University · CN

Funding

National Key Scientific Instrument and Equipment Development Projects of China HXHL21008National Natural Science Foundation of China 81672386National Natural Science Foundation of China 81803104National Natural Science Foundation of China 82172842Postdoctoral research and Development Fund and Translational medicine fund of West China Hospital 2020HXBH119Postdoctoral research and Development Fund and Translational medicine fund of West China Hospital CGZH19002Sichuan Province Science and Technology Support Program 2021YFSY008the Sichuan Province Science and Technology Support Program 2020YFS0276the Technology Innovation Project of Chengdu Science and Technology Bureau 2019-YF05-00459-SN
6 · The paper itself

Abstract

backgroundControversial findings have been reported in the impact of speckle-type POZ protein (SPOP) on clinicopathological features and prognosis in diverse cancers. We conducted this meta-analysis to confirm whether SPOP was an effective biomarker to predict clinical stage, cancer differentiation and survival.

methodsWe searched studies published before June 2021 through Medline, Embase, the Cochrane library register of controlled trials and Wanfang databases. The corrections of SPOP expression with expression disparity, tumor differentiation, clinical stage and survival were analyzed.

resultsOur meta-analysis found that higher expression of SPOP was significantly associated with earlier clinical stage, well differentiation and better overall survival. Subgroup analysis showed that the SPOP expression of adjacent tissue was significantly higher than that in cancer tissues of prostate and liver. However, renal cancer presented improved expression of SPOP in cancer tissue.

conclusionsSPOP has the potential function to act as a novel and effective biomarker for cancer diagnosis and prognostic stratification.

Indexed as

BiomarkerCancerMeta-analysisSpeckle-type POZ protein

Identifiers

PMID34838022
PMCPMC8627083
OpenAlexW3215265138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.